Clik here to view.
Kolmar Korea Wins Case Against Italian Cosmetics Maker Intercos for Suncare...
SEOUL, South Korea Kolmar Korea (KRX:161890), a Korean cosmetics ODM (Original Development Manufacturing) company, has announced its victory in a lawsuit against Intercos Korea, the Korean...
View ArticleClik here to view.
METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
スイス・ロート （ビジネスワイヤ） — ノボキュア（NASDAQ: NVCR）は、定位放射線手術（SRS）後に非小細胞肺がん（NSCLC）の頭蓋内転移が1～10箇所ある患者を対象に、脳腫瘍に対する腫瘍治療電場（Tumor Treating...
View ArticleClik here to view.
Charles River Announces Extension of Gene Therapy Manufacturing Alliance with...
WILMINGTON, Mass. Charles River Laboratories International, Inc. (NYSE: CRL) and National University of Singapore’s (NUS) Yong Loo Lin School of Medicine (NUS Medicine), a leading medical education...
View ArticleClik here to view.
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for...
TOKYO & BASKING RIDGE, N.J. Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the...
View ArticleClik here to view.
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing...
SHANGHAI & CAMBRIDGE, Mass. Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that two poster presentations highlighting ongoing global clinical studies in its oncology pipeline will be...
View ArticleClik here to view.
Asahi Kasei Bioprocess’ Massachusetts Training Center Expands 2024 Course...
TOKYO & NEW YORK & DÜSSELDORF, Germany Asahi Kasei Bioprocess’ (AKB) Massachusetts Training Center has announced an expansion of 2024 class offerings designed for individuals across various...
View ArticleClik here to view.
Skoll Foundation Announces the Winners of 2024 Skoll Award for Social Innovation
PALO ALTO, Calif. The Skoll Foundation has announced the four organizations that will receive the 2024 Skoll Award for Social Innovation, which highlights leaders and organizations that advance...
View ArticleClik here to view.
Kazakhstan Startup CerebraAI Relocates Headquarters to Silicon Valley to...
PALO ALTO, Calif. CerebraAI, an AI-driven neuroradiology software company focused on acute ischemic stroke detection, has relocated its headquarters to the U.S. from Kazakhstan, joining the new...
View ArticleClik here to view.
Worldwide Anti-Smoking Policies Charted in Comprehensive Index
BRUSSELS We Are Innovation, a leading global innovation network, released the 2024 Effective Anti-Smoking Policies Global Index (https://antismoking.global/). The index assesses around 5.5 billion...
View ArticleClik here to view.
综合指数描绘全球禁烟政策
布鲁塞尔 (美国商业资讯)– 全球领先的创新网络We Are Innovation发布了 2024年全球有效禁烟政策指数 (https://antismoking.global/)。该指数评估了约55亿人，即世界人口的近70%。它对四个地区69个国家的公共禁烟政策进行了分析。该指数深入探讨了替代尼古丁产品的复杂性，仔细研究了监管框架、禁令、税收和政府为戒烟采取的措施等方面。...
View ArticleClik here to view.
世界の禁煙政策をまとめた総合指標
ブリュッセル （ビジネスワイヤ） — グローバル・イノベーション・ネットワークのリーダーであるWe Are Innovationは、 2024年版効果的な禁煙政策グローバル指標...
View ArticleClik here to view.
Merck Foundation announced ‘‘Diabetes and Hypertension’’ Media Recognition...
MUMBAI, India Merck Foundation (www.merck-foundation.com), the philanthropic arm of Merck KGaA Germany announced the call for applications for their Media Recognition ‘Diabetes & Hypertension’...
View ArticleClik here to view.
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab)...
SHANGHAI, China & JERSEY CITY, N.J. Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the phase 3 comparative clinical trial for the investigational Prolia® and...
View ArticleClik here to view.
Propanc Biopharma’s CEO Shares Views on Revolutionizing Cancer Treatment: An...
MELBOURNE, Australia Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and...
View ArticleClik here to view.
Prolia ® 和Xgeva ® (denosumab)生物仿制药候选药物HLX14的3期比较临床研究达到主要终点
中国上海和新泽西州杰西市 (美国商业资讯)– Shanghai Henlius Biotech, Inc. (2696.HK)和Organon (NYSE:OGN)宣布，研究性Prolia®和Xgeva®...
View ArticleClik here to view.
Prolia ® とXgeva ® （デノスマブ）との第3相比較臨床試験でバイオシミラー候補HLX14が主要評価項目を達成
SHANGHAI, China & JERSEY CITY, N.J. （ビジネスワイヤ） — シャンハイ・ヘンリウス・バイオテック（2696.HK）とオルガノン（NYSE:...
View ArticleClik here to view.
Ferronova – Nanoparticle Trial Begins in Patients With Gastric and...
ADELAIDE, Australia Australian biotech company Ferronova has announced the initiation of a clinical trial of the company’s FerroTrace® nanoparticle technology in patients with gastric and...
View ArticleClik here to view.
First Interim Analysis of PROSPER Study Details Patient-Reported Symptom...
TOKYO On Friday, 12th April, 2024, Professor Julia Scarisbrick of University of Birmingham presented interim findings from the Kyowa Kirin, Inc. (Kyowa Kirin, TSA: 4151)-sponsored study, “Real-World...
View ArticleClik here to view.
Codone Biotech to Present Data on its Suppressor-tRNA Platform in Disease...
SHANGHAI Codone Biotechnology, which develops transformative medicines based on Suppressor-tRNAs for patients with severe diseases caused by nonsense mutations (aka, Premature Termination Codons),...
View ArticleClik here to view.
Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power...
TOKYO Renesas Electronics Corporation (TSE:6723), a premier supplier of advanced semiconductor solutions, today expanded its timing solutions portfolio with a new ultra-low 25fs-rms clock solution...
View Article